BioCryst Pharmaceuticals BCRX Acquired in-process research and development

Other financials

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:AcquiredInProcessResearchAndDevelopment.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is BioCryst Pharmaceuticals's acquired in-process research and development?: BioCryst Pharmaceuticals (BCRX) reported acquired in-process research and development of $697.76M in Q1 2026.